NASDAQ OMX

Immunicum AB (publ) and Academic Collaborators Publish Preclinical Ilixadencel Mode of Action Data in Journal Oncoimmunology

Dela

Press Release

10 November 2017

Immunicum AB (publ) and Academic Collaborators Publish Preclinical Ilixadencel Mode of Action Data in Journal Oncoimmunology

Immunicum AB (publ; First North Premier: IMMU.ST), a biopharmaceutical company advancing a novel, immune-priming cancer treatment against a variety of solid tumors, today announced two online publications of preclinical studies investigating the mode of action of lead program ilixadencel in the prestigious scientific journal Oncoimmunology . The studies show the multiple ways in which ilixadencel, or corresponding allogeneic proinflammatory mouse dendritic cells, create an immune-priming environment. Excerpts of the in vitro study were recently presented in a poster at the Society for Immunotherapy of Cancer (SITC) 32 nd Annual Meeting http://bit.ly/2zq2eBZ .

The publications in Oncoimmunology conducted in collaboration with Professor Magnus Essand's research group at Uppsala University, showed the following:

  • Ilixadencel addresses several key complementary immunological mechanisms to increase the capacity of the immune system to more efficiently recognize and destroy tumor cells.
  • Additional data from the cell culture studies demonstrated that ilixadencel boosts the ability of bystander dendritic cells (corresponding to the patients dendritic cells) to capture, process and present released tumor antigens leading to a subsequent activation of tumor-specific cytotoxic T-cells, which are important in the effective long-term destruction of tumor cells.
  • In the mouse tumor models, researchers were able to show that a local subcutaneous injection of allogeneic proinflammatory mouse dendritic cells (alloDCs) induced migration of activated host dendritic cells to the draining lymph node. Intratumoral injection of alloDCs furthermore altered the immunosuppressive tumor micro-environment in these mice resulting in a pro-inflammatory milieu that led to the recruitment of NK cells and CD8+ T cells to the treated tumor.

"The new data that now has been published, show the ability of ilixadencel, and corresponding allogeneic proinflammatory mouse dendritic cells, to stimulate several very important mechanisms to induce tumor-specific immune responses," said Alex Karlsson-Parra, Chief Scientific Officer of Immunicum. "The results further underscore the impact our technology could have in modern cancer treatment regimens and is in line with the promising signs of efficacy we have seen in the clinical trials with ilixadencel."

As part of the expanded data on ilixadencel's mode of action, the two studies also investigated the novel approach Immunicum is evaluating for potential subcutaneous injection in certain types of tumor diseases. This approach is based on the same principles as for ilxadencel with the addition of Immunicum's proprietary adenovirus vector Ad5PTDf35 used for transfection of ilixadencel with genes coding for tumor-specific antigens. Using this model, the researchers could replicate the immune system priming effect seen with non-transfected ilixadencel in vitro and mouse alloDC in vivo. Additional studies are needed to investigate the benefits and the safety profile to define the capabilities of this novel approach and how it could complement Immunicum's pipeline.

Immunicum's lead program ilixadencel has been tested in over 85 patients to date. Completed Phase 1/2 studies in renal cell carcinoma and hepatocellular carcinoma have shown a favourble  safety profile and initial signs of efficacy. There is  clinical development ongoing in a Phase 2 trial in renal cell carcinoma (MERECA) as well as a Phase 1/2 study in gastrointestinal stromal tumors (GIST).

The full publications titled "Pro-inflammatory allogeneic DC's promote activation of bystander immune cells and thereby license antigen specific T-cell responses" and "Cancer vaccine based on a combination of an infection-enhanced adenoviral vector and pro-inflammatory allogeneic DCs lead to sustained antigen-specific immune responses in three melanoma models" can be accessed through the current online version of Oncoimmunology and the following link. http://bit.ly/2j9pePF

About ilixadencel
Ilixadencel cell therapy product (formerly known as INTUVAX®) is an off-the-shelf cancer immune primer, developed for the treatment of solid tumors. Its active ingredient is activated allogeneic dendritic cells, derived from healthy blood donors. Intratumoral injection of these cells is expected to lead to an inflammatory response which in turn leads to tumor-specific activation of the patient's cytotoxic T-lymphocytes.

For more information, please contact:

Carlos de Sousa, CEO, Immunicum
Telephone: +46 (0) 31 41 50 52
E-mail: info@immunicum.com

Investor Relations Sweden

Helena Stångberg
Hallvarsson & Halvarsson
Telephone: + 46 709 71 12 53
E-mail: ir@immunicum.com

Investor and Media Relations EU/US

MacDougall Biomedical Communications
Gretchen Schweitzer or Stephanie May
Telephone: +49 89 2424 3494 or +49 175 5711562
E-mail: ir@immunicum.com

The Company's Certified Adviser is Redeye AB
Telephone: +46 (0)8 545 013 30
www.redeye.se

About Immunicum AB (publ)

Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient's own immune system to fight cancer. The company's lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq First North Premier. www.immunicum.com

 



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Immunicum AB via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

SEMAFO Mourns Passing of Board Chairman Jean Lamarre23.11.2017 22:01Pressmeddelande

MONTREAL, Nov. 23, 2017 (GLOBE NEWSWIRE) -- SEMAFO (TSX:SMF) (OMX:SMF) announces with sadness the passing of Mr. Jean Lamarre, Chairman of the Board of Directors of the Corporation, on November 22, 2017 following a short illness. Mr. Lamarre joined the Corporation's Board of Directors in 1997 and was appointed Chairman of the Board in 2000, a position he held until his demise. "Jean made an indelible mark on SEMAFO, both in terms of his corporate governance expertise and his 45 years of experience in Africa," said President and CEO Benoit Desormeaux. "Over his 20-year tenure with SEMAFO, he brought unique insight, business acumen and leadership to the Corporation as it transitioned from an exploration company to a junior gold producer. He did this, always without compromising his values: the integrity of the Corporation, his deep love for Africa and its people, and his priority to SEMAFO's long-term sustainability. On behalf of SEMAFO's Board of Directors, management and employe

Premier to join industry leaders at BDA London forum23.11.2017 21:39Pressmeddelande

HAMILTON, Bermuda, Nov. 23, 2017 (GLOBE NEWSWIRE) -- Premier David Burt will join more than two-dozen Bermuda executives in a multi-industry forum being held in London next week to showcase the breadth of expertise and advantages offered by the island's global business market. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/78c5ac53-07f7-4dd8-83e0-753ea5b4c80b Organised by the Bermuda Business Development Agency (BDA), the one-day event Tuesday, November 28 at ME London has attracted over 200 registrants. It will feature top regulatory and industry leaders in moderated discussion panels covering re/insurance, captive insurance, insurance-linked securities, asset management, family offices, and trust and private-client business. A networking reception will wrap the event in the evening. "The government supports the Bermuda Business Development Agency in this awareness-raising event that offers such gre

Crown Bioscience and Data Sciences International (DSI) Partner to Advance Metabolic Disease Research Using an Implanted Telemetry Device for Long-Term Blood Glucose Monitoring23.11.2017 14:00Pressmeddelande

SANTA CLARA, Calif., Nov. 23, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation cardiovascular and metabolic disease research, announces the successful development of an enhanced method for preclinical obesity and type 2 diabetes studies in partnership with Data Sciences International (DSI). Crown Bioscience's clinically relevant models and DSI's HD-XG implantable glucose device combine to create a superior approach to preclinical metabolic disease research. Recently published work in the Journal of Endocrinological Investigation and Nature's Scientific Reports demonstrates the advantages of a new method using DSI's HD-XG implantable glucose device and Crown Bioscience's models of spontaneous and diet-induced diabetes. The HD-XG device allows for continuous, long-term measurement

LeoVegas AB: Valberedning utsedd i LeoVegas inför årsstämma 201823.11.2017 11:50Pressmeddelande

Enligt de principer för valberedning i LeoVegas AB (publ) ("Bolaget" eller "LeoVegas") som antogs på årsstämman den 17 maj 2017 ska valberedningen bestå av fyra ledamöter utsedda av de tre största aktieägarna per den 30 september 2017, jämte styrelsens ordförande. Baserat på ovanstående har valberedningen inför årsstämman 2018 fastställts till att bestå av följande personer som tillsammans representerar cirka 23 procent av antalet aktier och röster i Bolaget per den 30 september 2017: Anders Fast, valberedningens ordförande och utsedd av Gustaf Hagman Joachim Spetz, utsedd av Swedbank Robur Fonder Dan-Alp Lindberg utsedd Robin Ramm-Ericson Mårten Forste, styrelseordförande Valberedningens förslag kommer att presenteras i kallelsen till årsstämman 2018 samt på bolagets hemsida, www.leovegasgroup.com.

LeoVegas AB: Nomination committed appointed for LeoVegas ahead of 2018 Annual General Meeting23.11.2017 11:50Pressmeddelande

In accordance with the principles for appointment of a nomination committee of LeoVegas AB (publ) ("the Company" or "LeoVegas") that were adopted by the Annual General Meeting on 17 May 2017, the Nomination Committee shall consist of four members appointed by the three largest shareholders as at 30 September 2017, together with the Chairman of the Board. Based on the above, the Nomination Committee ahead of the 2018 Annual General Meeting has been determined to consist of the following persons, who represent approximately 23% of the number of shares and votes in the Company as per 30 September 2017: Anders Fast, Nomination Committee chair, representing Gustaf Hagman Joachim Spetz, representing Swedbank Robur Fonder Dan-Alp Lindberg, representing Robin Ramm-Ericson Mårten Forste, Chairman of the Board The No

Hemcheck Sweden AB: Viktigt patent beviljat av PRV23.11.2017 09:00Pressmeddelande

PRESSMEDDELANDE   Viktigt patent beviljas av PRV PRV, det svenska patent och registreringsverket, meddelar att HemChecks patentansökan gällande bolagets blodseparationsteknik kommer att beviljas för Sverige den 19 december 2017. Patentets publiceringsnummer kommer att bli 539853. -För HemCheck är patentet strategiskt mycket viktigt, eftersom det innefattar vår teknik för blodseparation. Det skyddar den teknik som gör att en ej definierad blodvolym kan användas i vårt engångstest och det är just det som gör vårt hemolystest så unikt, enkelt och användarvänligt - och dessutom mycket snabbt. I kombination med övriga patent har vi nu ett mycket bra skydd för den metod som HemChecks affärsidé i grunden bygger på, säger vd Annelie Brolinson i en kommentar. En internationell patentansökan har lämnats in för att söka skydd på övriga viktiga marknader.  För ytterligare information, kontakta: Hemcheck Sweden AB

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum